CAMBRIDGE, Mass., Aug 24 - Insilico Medicine (“Insilico”; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the launch of the Open Drug Discovery and Development Consortium (O3DC) - www.o3dc.org, an open initiative addressing how computational drug discovery methods are evaluated, together with its first shared resource: a community-curated index of the benchmarks the field relies on.

The 4-week individualized, dose-controlled HD-tDCS combined with foot core exercise intervention improved sensorimotor function, reduced cortical activation during dorsi-plantarflexion tasks, and enhanced functional connectivity (FC) within related brain regions in individuals with chronic ankle instability. Lower cortical activation and higher increased related FC are associated with better ankle force sense. These findings indicated that this kind of combined intervention—simultaneously targeting cerebral cortex and peripheral ankle dysfunction—offers greater benefits than traditional functional training alone.

This study provides the first comprehensive estimation of the lifetime risk (LTR) of digestive system cancers in China using the Global Burden of Disease (GBD) 2023 data. With a 11.36% LTR for incidence and 8.28% for mortality, the findings highlight a profound public health challenge. Significant male-to-female and regional disparities—particularly the high burden in East China—underscore the urgent need for geographically tailored screening programs and primary prevention to mitigate this escalating health threat.

A recent review in the Chinese Medical Journal highlights how tryptophan metabolism regulates female reproductive health via three pathways—kynurenine, serotonin, and indole. These pathways influence ovarian function, immune regulation, and pregnancy outcomes. The review also proposes potential interventions including diet and microbiota modulation, while noting more research is needed for precise mechanisms and clinical applications.